NASDAQ:OTIC
Delisted
Otonomy Stock News
$0.0085
+0 (+0%)
At Close: Jul 11, 2023
Otonomy to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
07:30am, Thursday, 17'th Feb 2022
SAN DIEGO, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will
Otonomy Inc.s (OTIC) $2.00: At This Price, Its Worthwhile
02:00pm, Saturday, 04'th Dec 2021 Stocks Register
Otonomy Inc. (NASDAQ:OTIC) concluded the trading at $2.00 on Friday, December 03 with a fall of -3.38% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $2.07 and 5Y monthly beta was reading 2.01 with its price kept floating in the range Otonomy Inc.s (OTIC) $2.00: At This Price, Its Worthwhile Read More »
Geode Capital Management LLC Has $953,000 Stock Position in Otonomy, Inc. (NASDAQ:OTIC)
09:06am, Tuesday, 23'rd Nov 2021 Transcript Daily
Geode Capital Management LLC increased its stake in shares of Otonomy, Inc. (NASDAQ:OTIC) by 2.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 427,394 shares of the biopharmaceutical company’s stock after buying an additional 11,204 shares during the period. […]
Otonomy (NASDAQ:OTIC) Lowered to Sell at Zacks Investment Research
08:44am, Wednesday, 17'th Nov 2021 Dakota Financial News
Zacks Investment Research downgraded shares of Otonomy (NASDAQ:OTIC) from a hold rating to a sell rating in a report published on Tuesday, Zacks.com reports. According to Zacks, Otonomy, Inc. engages in developing and commercializing therapeutics to address unmet medical needs in the otology market. It develops therapeutics for treatment of inner and middle ear disorders. []
Otonomy to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
12:30pm, Tuesday, 16'th Nov 2021 Intrado Digital Media
SAN DIEGO, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference. Management will participate in a pre-recorded company fireside chat, which will be available on the conference website beginning at 10 a.m. ET / 7 a.m. PT on November 22, 2021.
Otonomy (OTIC) Reports Q3 Loss, Lags Revenue Estimates
08:36pm, Wednesday, 10'th Nov 2021
Otonomy (OTIC) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus Improvement in Patients Receiving OTO-313
07:30am, Tuesday, 12'th Oct 2021
SAN DIEGO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pub
Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS Annual Meeting
07:30am, Monday, 27'th Sep 2021
SAN DIEGO, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the pr
Otonomy to Participate in Two Upcoming Investor Conferences
07:30am, Thursday, 02'nd Sep 2021
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that m
Otonomy Appoints Jill Broadfoot to Board of Directors
07:30am, Thursday, 19'th Aug 2021
SAN DIEGO, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the app
Otonomy Reports Second Quarter 2021 Financial Results and Provides Corporate Update
04:16pm, Wednesday, 04'th Aug 2021
Conference call and webcast today at 4:30 p.m. ET
Otonomy to Report Second Quarter 2021 Financial Results and Provide Corporate Update
07:30am, Wednesday, 28'th Jul 2021
SAN DIEGO, July 28, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will
Will Otonomy (OTIC) Report Negative Q2 Earnings? What You Should Know
04:05pm, Tuesday, 27'th Jul 2021
Otonomy (OTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Otonomy Initiates Expansion of Phase 1/2 Clinical Trial for OTO-413 in Hearing Loss
07:30am, Tuesday, 15'th Jun 2021
SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the ini
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825 Gene Therapy at ASGCT Annual Meeting
07:30am, Friday, 14'th May 2021
OTO-825 administration rescues hearing and cochlear damage in two preclinical models of congenital hearing loss caused by GJB2 deficiency OTO-825 administration rescues hearing and cochlear damage in